dexamethasone + asparaginase + gemcitabine

This is a combination chemotherapy regimen consisting of dexamethasone, asparaginase (or its pegylated form pegaspargase), and gemcitabine. Each component has a distinct mechanism of action: - Dexamethasone is a synthetic glucocorticoid with anti-inflammatory and immunosuppressive properties, commonly used to induce apoptosis in lymphoid cells. - Asparaginase is an enzyme that depletes extracellular asparagine, an amino acid essential for the survival of certain malignant lymphoid cells, leading to inhibition of protein synthesis and cell death. - Gemcitabine is a nucleoside analog antimetabolite that inhibits DNA synthesis by incorporation into DNA strands during replication, resulting in apoptosis. This combination has been studied primarily for the treatment of extranodal natural killer/T-cell lymphoma (ENKTL), where it forms part of multi-agent regimens such as DDGP (dexamethasone, cisplatin, gemcitabine, pegaspargase) or similar protocols. The regimen leverages synergistic cytotoxic effects on malignant lymphoid cells and has demonstrated high response rates in clinical studies[5][6]. The combination may be used alone or with other agents depending on protocol specifics.